We extend the approach of finding effective sample size for a typical phase II clinical trial having efficacy and toxicity as two components of the response vector. The case of binary efficacy and binary toxicity is illustrated under Dirichlet and multivariate T priors.
Keywords: Dirichlet prior; efficacy; multivariate T; toxicity.
© 2020 The International Biometric Society.